Techniques of Surgery and Radiotherapy for Multimodal Treatment of Pleural Mesothelioma

Pierre Bonnette
2011 Journal of Thoracic Oncology  
this result should be interpreted with caution because only 30 patients in the study had EGFR-mutated tumors and the 95% confidence intervals for the HRs were wide (upper limit Ͼ1) and overlapping; however taking account of this promising data, bevacizumab combined with EGFRtyrosine kinase inhibitor is attractive for patients with EGFR mutations and randomized studies are warranted.
doi:10.1097/jto.0b013e3182377281 pmid:22088997 fatcat:76jnx7opcvgjxmdkhylnsww2uu